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The Netherlands
Objectives: Peripheral arterial occlusive disease (PAOD) is associated with a high risk of cardiovascular events. The metabolic
syndrome is a frequent condition among patients with manifest vascular disease, but the influence of the metabolic syndrome
on cardiovascular events in patients with PAOD is unknown. Also, progression and regression of themetabolic syndrome after
follow-up are not extensively studied.
Methods:The study population consisted of 461 patients with symptomatic PAOD from the SecondManifestations of Arterial
Disease study (SMART). Patients underwent vascular screening at baseline and after a mean follow-up of 5.5  1.3 years.
Hazard ratios (HRs) for vascular events according to metabolic syndrome status (updated National Cholesterol Education
Program [NCEP] criteria) were calculated using Cox regression analysis. The course of the metabolic syndrome during
follow-up and the influence of body mass index (BMI) on development or disappearance of the syndrome were assessed.
Results:During follow-up, 91 first vascular events were recorded. Cumulative 3-year survival free from vascular events was
84.7% inmetabolic syndrome patients compared to 92.1% in participants without the syndrome. Themetabolic syndrome
was associated with an increased risk of vascular events (HR 1.51; 1.01-2.30, age- and gender-adjusted). During
follow-up, 128 patients died or were lost to follow-up, and of 333 remaining patients, 221 participated in follow-up
measurements. The metabolic syndrome disappeared in 16% of patients and was incident in 14% of patients during
follow-up. Waist circumference increased with 10 8 cm in those developing the syndrome. A BMI decrease of 1 kg/m2
significantly decreased the risk of metabolic syndrome development by 23% (odds ratio [OR] 0.77; 0.62-0.96), and
increased the chance to revert to a non-metabolic syndrome state by 32% (OR 1.32; 1.03-1.71).
Conclusion: The metabolic syndrome is associated with a 1.5-fold increase in risk of vascular events in PAOD patients.
Weight control reduces metabolic syndrome incidence and increases metabolic syndrome resolution during follow-up.
(J Vasc Surg 2009;50:61-9.)Peripheral arterial disease (PAOD) is most often the
result of atherosclerosis in the arteries of the lower extrem-
ities and is associated with a high risk of vascular events at
other sites of the vasculature (myocardial infarction, stroke)
and death.1-4 Risk factors for developing vascular compli-
cations in PAOD patients are hypertension, hypercholes-
terolemia, diabetes, smoking, and atherosclerotic vascular
diseases in other vascular beds.4 Often vascular risk factors
cluster in single patients as the result of central obesity,
referred to as metabolic syndrome.
The metabolic syndrome is defined as the clustering
of at least three risk factors such as abdominal obesity,
hypertension, hyperglycemia, hypertriglyceridemia, and
low high-density lipoproteins (HDL)-cholesterol levels.
The age-dependent prevalence of the metabolic syndrome
is between 20% and 40% in healthy subjects,5 whereas the
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doi:10.1016/j.jvs.2008.12.070metabolic syndrome is present in 45% of patients with
manifest vascular disease.6 In particular, in patients with
PAOD, the condition is remarkably frequent, with preva-
lences of 52% and 58% reported for this population.6,7
Presence of metabolic syndrome in PAOD patients is asso-
ciated with advanced vascular damage.8
In populations free of cardiovascular disease at baseline,
cardiovascular morbidity and mortality increased 1.5 to
3-fold in the presence of the metabolic syndrome.9,10 Also,
in patients with a history of myocardial infarction or coro-
nary heart disease, the metabolic syndrome was associated
with increased risks of cardiovascular events or death.9,11-14
Considering the high absolute risk of vascular morbid-
ity and mortality in PAOD patients, the high prevalence of
the metabolic syndrome in this population, as well as the
increased vascular risk accompanied by the metabolic syn-
drome, might be an important condition in patients with
PAOD.
Given the high prevalence of the metabolic syndrome
in PAOD patients, it is also important to gain understand-
ing about how the metabolic syndrome develops over time.
No information is currently available on the course of the
metabolic syndrome or on possible improvements or wors-
ening in individual metabolic syndrome characteristics in
patients with PAOD.
The aim of this prospective cohort study was to quan-
tify the risk of vascular events associated with the metabolic
syndrome in PAOD patients. Second, we studied determi-
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appearance during follow-up as well as the changes in
individual metabolic syndrome components.
METHODS
Study population. The patients included in this study
originated from the Second Manifestations of ARTerial
disease (SMART) study. The SMART study is an ongoing
single-center prospective cohort study that was designed to
establish the presence of additional arterial disease and risk
factors for atherosclerosis in patients with manifest vascular
disease or a vascular risk factor. Since 1996, more than
8000 patients aged 18-80 years with atherosclerotic vascu-
lar disease (cerebrovascular disease, coronary heart disease,
PAOD, or abdominal aortic aneurysm [AAA]) or risk fac-
tors for atherosclerosis (hyperlipidemia, diabetes, or hyper-
tension) have been included. The study was approved by
the local ethics committee and all patients gave written
informed consent. Rationale and design of the SMART
study have been described previously.15
The current study was based on the data of SMART
participants included because of PAOD. These patients
were referred to the Department of Vascular Surgery of the
University Medical Center Utrecht with symptomatic
PAOD (intermittent claudication, non-healing ulcers, or
gangrene) and had a resting ankle brachial pressure index
(ABI) less than or equal to 0.90. The data of 461 consec-
utive patients included in the screening program between
September 1996 and December 2000 were available for
analysis.16 Patients were invited to visit the hospital again
for a follow-up measurement in the period between Sep-
tember 2003 and March 2005. In the intervening period,
patients received usual care from their own general practi-
tioner or vascular specialist.
Vascular screening. Patients underwent standardized
screening for detection of manifestations of atherosclerotic
disease and vascular risk factors both at baseline and after
follow-up. Participants completed a questionnaire on car-
diovascular history, medication use, and risk factors. Sever-
ity of PAOD was classified according to the Fontaine
classification.17 After an overnight fast, patients visited the
hospital where a physical examination was carried out,
consisting of measurements of weight, height, waist and
hip circumferences, and blood pressure (BP). Measure-
ments were performed according to a standardized proto-
col. Fasting blood was sampled to ascertain levels of glu-
cose, total cholesterol, HDL-cholesterol, triglycerides,
creatinine, and homocysteine. Low-density lipoprotein
(LDL)-cholesterol levels were calculated with Friedewald’s
formula. Morning urine samples were collected to measure
albumin and creatinine concentrations. All assessments
were performed at a single laboratory. An ABI was assessed
for each leg by calculating ratios of the highest systolic BP
measured at the ankle to the highest systolic BP in both
arms with the patient in the supine position. Systolic BP in
the posterior tibial and dorsal pedal arteries (left and right)
was measured with an 8-MHz continuous-wave Doppler
probe connected to an IMEXLAB 9000 Vascular Diagnos-tic System (Imex Medical Systems Inc, Golden, Colo).
Systolic BP in both brachial arteries was determined with a
semiautomatic oscillometric device (Omega 1400, Invivo
Research Laboratories Inc, Broken Arrow, Okla). Screen-
ing also included duplex scanning of the carotid arteries,
electrocardiography, and ultrasonography of the abdomen
with measurements of the anteroposterior aortic and juxta-
renal diameter. Results of the screening and recommenda-
tions for treatment, formulated by a team of medical spe-
cialists, were reported to the general practitioner and other
treating specialists. The techniques of the baseline exami-
nations have been published formerly.15
Definitions. Metabolic syndrome was defined as the
presence of 3 or more of the following: (1) waist circum-
ference 88 cm in women and 102 cm in men; (2)
fasting triglycerides1.70 mmol/L (150 mg/dL) or drug
treatment for elevated triglycerides; (3) HDL-cholesterol
1.30 mmol/L (50 mg/dL) in women and 1.03
mmol/L in men (40 mg/dL) or drug treatment for re-
duced HDL-cholesterol; (4) BP 130/85 mm Hg or use
of BP-lowering medication; and (5) fasting glucose 5.6
mmol/L (100 mg/dL) or use of glucose-lowering med-
ication, according to the American Heart Association/
National Heart, Lung, & Blood Institute (AHA/NHLBI)
updatedNational Cholesterol Education Program (NCEP)
Adult Treatment Panel III (ATPIII) criteria.18 If waist
circumference was not available, a body mass index (BMI)
30 kg/m2 was used as a determinant for abdominal
obesity.19 Hypertension was defined as diastolic BP 90
mm Hg, systolic BP 140 mm Hg, or self-reported use of
BP-lowering.20 Type 2 diabetes mellitus was defined as
self-reported type 2 diabetes, use of glucose-lowering
agents, or fasting glucose7.0 mmol/L at screening.21 In
this way, diabetes mellitus also included newly diagnosed
patients with diabetes mellitus. Patients were classified as
smoking when currently smoking or stopped smoking in
the year of inclusion in the SMART study.
The four-variable Modification of Diet in Renal Dis-
ease (MDRD) equation was used to calculate estimated
glomerular filtration rate (eGFR). At follow-up, the
homeostatic model assessment (HOMA) for insulin sen-
sitivity was added to the measurements to estimate insu-
lin resistance.22
Follow-up and outcome evaluation. Patients pro-
vided information on hospitalization and out-patient clinic
visits in response to a short questionnaire every 6 months.
When a cardiovascular event was reported, original source
documents were retrieved and reviewed to determine the
occurrence of cardiovascular disease. All possible events
were audited independently by three members of the End-
point Committee. Patients were followed until death or
refusal of further participation. The main outcome of inter-
est for this study was a composite of first occurrence of
stroke, myocardial infarction, or vascular death. Definitions
of events are shown in Table I.
Statistical analysis. Results are expressed as means
with standard deviations or as percentages unless otherwise
stated. Crude overall cumulative survival after 1 and 3 years
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gender-adjusted cumulative incidence of vascular events
and of vascular interventions according to the presence or
absence of the metabolic syndrome at baseline was evalu-
ated with the use of the Cox proportional hazards model.
Results are presented as hazard ratios (HRs) with 95%
confidence intervals (95% CIs). Patients without the meta-
bolic syndrome served as the reference category in the
analyses. The presence and extent of confounding was
assessed by comparing the crude HR with the adjusted HR
derived from themodel containing the potential confound-
ing variable. Potential confounders were factors related to
the determinant (metabolic syndrome) as well as to the
outcome (occurrence of vascular events), but not part of
the causal chain of the metabolic syndrome. No adjustment
was made for variables, part of the metabolic syndrome, or
highly correlated to (components of) the metabolic syn-
drome.
Patients who underwent follow-up measurements were
classified into four categories according to the presence
of metabolic syndrome at baseline and at follow-up: (1)
patients without metabolic syndrome at baseline and at
follow-up; (2) patients withmetabolic syndrome at baseline
but not at follow-up; (3) patients with metabolic syndrome
at follow-up but not at baseline; (4) patients with metabolic
syndrome at baseline and at follow-up. Changes in meta-
bolic syndrome components are presented according to
these groups. Logistic regression analysis was performed to
evaluate the effect of baseline BMI and of change in BMI
on development and losing of the metabolic syndrome
during follow-up. Adjustments were made for age and
Table I. Definitions of events
Vascular death  Sudden death (unexpected cardiac death
occurring within 1 hour after onset of
symptoms, or within 24 hours given con-
vincing circumstantial evidence).
 Death from ischemic stroke, intracerebral
hemorrhage, myocardial infarction, conges-
tive heart failure, or AAA rupture.
Stroke  Definite: relevant clinical features causing
an increase in impairment of at least one
grade on the modified Rankin scale, accom-
panied by an infarction or hemorrhage on a
repeat CT scan.
 Probable: clinical deficits causing an in-
crease in impairment of at least one grade
on the modified Rankin scale, without CT
documentation.
Myocardial
infarction
 At least two of the following criteria: (1)
chest pain for at least 20 minutes, not dis-
appearing after administration of nitrates;
(2) ST-elevation 1 mm in two following
leads or a left bundle branch block on the
electrocardiogram; (3) CK elevation of at
least two times the normal value of CK and
a myocardial band-fraction 5% of the total
CK.
AAA, Abdominal aortic aneurysm; CK, creatine kinase; CT, computed
tomography; ST, xxx.gender, and additionally for baseline BMI when a change inBMI was studied. All statistical analyses were performed
with SPSS 14.0 for Windows (SPSS, Chicago, Ill).
RESULTS
Study population. In the period between September
1996 and December 2000, 461 patients were included
based on a recent diagnosis of PAOD. The baseline char-
acteristics of these patients are shown in Table II. Of the
461 patients, 20 (4%) were lost to follow-up and 108 (23%)
had died before the time of the follow-up visit. Of the
remaining 333 patients, 112 (34%) refused further partici-
Table II. Baseline characteristics of 461 patients with
PAOD according to metabolic syndrome presence
Metabolic
syndrome 
Metabolic
syndrome 
n  234 n  227
Male gender (%) 67.9 67.4
Age (years) 60  11 60  11
Fontaine classification 2 (%) 87 84
Fontaine classification 3 or 4 (%) 13 16
Ankle-brachial index 0.83  0.20 0.82  0.21
Additional cerebrovascular
disease (%) 12.4 20.7
Additional coronary heart
disease (%) 28.2 27.3
Additional AAA (%) 6.4 7.0
Diabetes mellitusa (%) 9.9 40.4
Smoking (%) 63 54
Pack years of smoking 27.2  19.5 28.4  20.3
Physical activityb (%) 22.7 17.5
Body mass index (kg/m2) 24.0  2.9 27.4  4.1
LDL-cholesterol (mmol/L) 3.8  1.0 3.9  1.0
Homocysteine (mol/L) 15.4  11.3 14.5  5.8
eGFR (ml/min/1.73m2) 76  20 74  21
Albuminuria (%)c 17.3 23.1
Subcutaneous fat (cm) 2.6  2.5 2.8  1.5
Intra-abdominal fat (cm) 8.5  2.0 10.6  2.1
Metabolic syndrome
components
Waist circumference (cm) 90  8 99  11
Systolic BP (mm Hg) 143  22 151  21
Diastolic BP (mm Hg) 78  11 81  11
HDL-cholesterol (mmol/L) 1.3  0.4 1.0  0.2
Triglycerides (mmol/L) 1.6  1.0 2.7  1.6
Fasting glucose (mmol/L) 5.7  1.5 7.2  2.6
Treatment at baseline
Glucose-lowering agents (%) 7.3 24.2
Lipid-lowering agents (%) 24.9 33.5
Blood pressure-lowering
agents (%) 24.8 40.4
Antithrombotic agents (%) 42.7 41.9
AAA, Abdominal aortic aneurysm; LDL, low-density lipoprotein; eGFR,
estimated glomerular filtration rate, calculated with MDRD equation; BP,
blood pressure; HDL, high-density lipoproteins; MDRD, Modification of
Diet in Renal Disease.
aDefined as self-reported type 2 diabetes, use of glucose lowering agents or
fasting glucose 7.0 mmol/L.
bSelf-reported exercising.
cAlbumin-to-creatinine rate 3 mg/mmol. Waist circumference was mea-
sured in 179 individuals, and measurements of intra-abdominal and subcu-
taneous fat were present for 51 patients. Continuous variables are expressed
as means with standard deviations.pation and 221 (66%) underwent follow-up measurements
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patients who did and did not participate in the follow-up
measurements are presented in Table III. The largest dif-
ferences were found between those who participated in the
follow-up examination and those who died before the
follow-up examination, but differences were also present
between those who agreed and those who refused to par-
ticipate. Participants were more often male (67% vs 61%),
were generally younger (57 vs 60 years), less often had a
history of cerebrovascular disease (9.5% vs 19.7%) or dia-
betes mellitus (14.9% vs 34.6%), and had lower mean
glucose levels (6.0 vs 7.0 mmol/L). The proportion of
patients using medication was lower in participants com-
pared with non-participants.
Metabolic syndrome and vascular events. The met-
abolic syndrome was present in 49% of the study popula-
tion. Of the individual metabolic syndrome components,
the BP criterion was most frequent and was present in 83%
of patients, followed by the criterion for HDL-cholesterol
(54%), triglycerides (53%), and glucose (42%). The crite-
rion for waist circumference was present in 19% of subjects.
During a mean follow-up of 5.6  1.4 years, 91 pa-
tients experienced one or more vascular events (first event:
23 myocardial infarctions, 22 strokes, and 46 vascular
deaths). Crude cumulative 1-year survival free from vascu-
lar events was 94.6% (92.4-96.8%) and declined to 88.4%
(85.5-91.3%) after 3 years. In patients without the meta-
bolic syndrome, crude survival free from vascular events was
96.1% (93.6-98.6%) after 1 year and 92.1% (88.6-95.6%)
after 3 years of follow-up, compared to 92.9% (89.6-96.2%)
and 84.7% (80.0-89.4%) in patients with the metabolic syn-
drome. Fig 2 shows the cumulative incidence of vascular
events according to the presence or absence of the metabolic
syndrome, resulting from an age- and gender-adjusted Cox
regression analysis. Themetabolic syndrome increased the risk
of vascular events after adjustment for age and gender (HR
1.51; 1.01-2.30). There was no relation between presence of
individual metabolic syndrome components and the occur-
rence of vascular events (Table IV).
In additional analyses, no association was found be-
tween the metabolic syndrome and the occurrence of re-
vascularization procedures to the legs during follow-up
(age- and gender-adjusted HR 0.99; 95% CI 0.65-1.49)
and between the metabolic syndrome and the occurrence
of lower limb amputations (age- and gender-adjusted HR
Fig 1. Composition of the study population.1.59; 0.84-3.01). The metabolic syndrome also did notinfluence the occurrence of surgical and endovascular aortic
interventions (age- and gender-adjusted HR 1.11; 0.59-
2.10) or the occurrence of interventions to the carotid
arteries (age- and gender-adjusted HR 1.20; 0.49-2.95).
Change in metabolic syndrome status. Mean follow-
up among the 221 PAODpatients with follow-upmeasure-
ments was 5.5  1.3 years. Metabolic syndrome was diag-
nosed in 45% of the population at baseline and in 43% at
follow-up. The majority of patients (70%) remained at the
same status: 91 patients (41%) did not meet the metabolic
syndrome criteria at baseline and at follow-up, and 64
patients (29%) had the metabolic syndrome at both mea-
surements. In Table V, baseline characteristics, change in
metabolic syndrome components, and medication use is
shown according to four groups of metabolic syndrome
status at baseline and follow-up.
Patients with the metabolic syndrome at baseline and at
follow-up were older and showed highest values of waist
circumference (100  12 cm), systolic BP (150  19 mm
Hg), and triglycerides (2.8  1.4) as well as the lowest
HDL-cholesterol level (0.9  0.2 mmol/L). Change in
metabolic syndrome components according to metabolic
syndrome status at baseline and follow-up is shown in Fig 3.
Homeostatic model assessment insulin resistance (HOMA-
IR) measured at follow-up correlated well with metabolic
syndrome status and was highest among patients with
persistent metabolic syndrome.HOMA-IRwas also high in
patients with incident metabolic syndrome.
HDL-cholesterol was the criterion most frequently
lost. A total of 53.7% of patients fulfilling the HDL crite-
rion at baseline lost it after follow-up. Also the triglycerides
criterion was frequently lost (39.6%). The glucose criterion
was no longer present in 21.8% of the baseline cases. Fewer
patients were able to get their waist circumference below
the metabolic syndrome cut-off (10.8%) and almost none
lost the BP criterion (2.3%). Of the patients without the BP
criterion at baseline, 84% did meet the BP criterion at
follow-up and of patients without the HDL criterion at
baseline, 46% had the HDL criterion at follow-up. A total
of 36% of patients without the criterion for waist circum-
ference at baseline did have the criterion for waist circum-
ference at follow-up, and 20% of those without the triglyc-
erides criterion and 16% of those without the glucose
criterion at baseline fulfilled these criteria at follow-up.
Both baseline BMI and change in BMI during follow-
up were significantly associated with the development or
disappearance of the metabolic syndrome. Baseline BMI
was related to incident metabolic syndrome (odds ratio
[OR] 1.53; 1.23-1.90) and to the disappearance of meta-
bolic syndrome at follow-up (OR 0.87; 0.77-0.98) after
adjustment for age and gender. Per kg/m2 decrease in BMI
during follow-up, patients without themetabolic syndrome
at baseline decreased their risk to acquire the syndrome
during follow-up by 23% (OR 0.77; 0.62-0.96). Subjects
with the metabolic syndrome at baseline showed a 32%
(OR 1.32; 1.03-1.71) increase in chance to lose the syn-
drome during follow-up when they lowered their BMI by 1
kg/m2 (adjusted for age, gender, and baseline BMI).
s are e
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The metabolic syndrome is a frequent condition in
symptomatic PAOD patients with a prevalence of 49%.
Cumulative 3-year survival free from vascular events was
Table III. Differences in baseline characteristics between
Participants follow-
n  221
Male gender (%) 67.0
Age (years) 57  10
Fontaine classification 2 vs 3 or 4 (%) 87.8 vs 12.2
Ankle-brachial index 0.85  0.19
Additional cerebrovascular disease (%) 9.5
Additional coronary heart disease (%) 23.5
Additional AAA (%) 5.0
Diabetes mellitusa (%) 14.9
Smoking (%) 58.6
Pack years of smoking 26.6  18.7
Body mass index (kg/m2) 25.6  3.7
LDL-cholesterol (mmol/L) 4.0  1.0
Waist circumference (cm) 95  11
Systolic BP (mm Hg) 144  21
Diastolic BP (mm Hg) 80  10
HDL-cholesterol (mmol/L) 1.1  0.3
Triglycerides (mmol/L) 2.1  1.4
Fasting glucose (mmol/L) 6.0  1.5
Glucose-lowering agents (%) 8.2
Lipid-lowering agents (%) 28.8
Blood pressure-lowering agents (%) 26.8
Antithrombotic agents (%) 38.0
AAA, abdominal aortic aneurysm; LDL, low-density lipoprotein; BP, blood
Waist circumference was measured in 179 individuals. Continuous variable
aDefined as self-reported type 2 diabetes, use of glucose-lowering agents or
Fig 2. Cumulative incidence of vascular events according to pres-
ence or absence of themetabolic syndrome at baseline, adjusted for
age and gender. MS absent, Without metabolic syndrome; MS
present, with metabolic syndrome; HR, hazard ratio; CI, confi-
dence interval.84.7% in metabolic syndrome patients compared to 92.1%in participants without the metabolic syndrome. In the
present study, it was shown that the metabolic syndrome is
associated with a 1.51-fold increased risk for the develop-
ment of vascular events in patients with symptomatic
PAOD. The metabolic syndrome was not associated to
cipants and non-participants in the follow-up examination
Non-participants
and lost to follow-up Died before follow-up
n  132 n  108
61.4 76.9 *
60  11 67  10 *
85.1 vs 14.9 81.0 vs 19.0
0.79  0.19 0.80  0.23 *
19.7 26.9 *
22.7 42.6 *
4.5 13.0 *
34.6 33.6 *
60.8 55.1
28.9  21.9 29.0  19.9
26.1  4.2 25.2  3.8
3.8  1.1 3.8  1.0
96  12 95  12
149  21 152  24 *
80  11 78  12
1.2  0.4 1.1  0.4
2.4  1.3 2.0  1.4
7.0  2.7 6.7  2.4 *
22.3 22.4 *
33.3 24.5
33.1 43.0 *
41.7 51.9
ure; HDL, high-density lipoproteins.
xpressed as means with standard deviations.
g glucose 7.0 mmol/L. *Indicates P value .05.
Table IV. Effect of metabolic syndrome and its
components on the occurrence of vascular events
Prevalence HR (95% CI)
Metabolic syndrome 49% I 1.51 (1.00-2.30)
Blood pressure criteriona 83% I 0.79 (0.46-1.35)
II 0.75 (0.45-1.25)
HDL criterionb 54% I 1.09 (0.72-1.65)
II 1.00 (0.63-1.60)
Triglycerides criterionc 53% I 1.13 (0.75-1.71)
II 1.06 (0.67-1.70)
Waist criteriond 19% I 1.07 (0.92-1.25)
II 1.07 (0.91-1.24)
Glucose criterione 42% I 1.14 (0.89-1.47)
II 1.18 (0.90-1.56)
HR,Hazard ratio; CI, confidence interval;HDL, high-density lipoproteins.
Model I adjusted for age and gender; model II additionally adjusted for
other metabolic syndrome components.
aBlood pressure (BP)130/85 mmHg or use of BP-lowering medication.
bHDL cholesterol 1.29 mmol/L (50 mg/dL) in women and 1.04
mmol/L in men (40 mg/dL).
cFasting triglycerides 1.70 mmol/L (150 mg/dL).
dWaist circumference 88 cm in women and 102 cm in men.
eFasting glucose 6.1 mmol/L (110 mg/dL) or use of glucose-lowering
agents.parti
up
pressfuture vascular interventions and presence of individual
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an increased vascular risk. BMI at baseline as well as change
in BMI during follow-up had a large influence on incident
metabolic syndrome and on disappearance of metabolic
syndrome during follow-up.
The prevalence of metabolic syndrome in patients with
PAOD is high in the present study (49%), and is compara-
ble with other studies.6,7 In general, it is thought that
abdominal obesity is the driving force for the development
of insulin resistance resulting in the metabolic changes seen
in the metabolic syndrome.23,24 As exercise has beneficial
effects on insulin resistance25,26 and symptomatic PAOD
reduces the ability to ambulate, a decrease in physical
activity might be an important cause of insulin resistance in
this population. Other possible causes of insulin resistance
in this population include genetic predisposition27 and low
birth weight.28
In the present study, with 5.5 years of follow-up, it is
shown that presence of the metabolic syndrome signifi-
cantly increased the risk of vascular events in patients with
Table V. Baseline characteristics and changes in metabolic
metabolic syndrome status at baseline and after follow-up
Baseline
Follow-up
n  91
Baseline characteristicsa
Male gender (%) 63.7
Age (years) 56  10
Smoking (%) 58.2
Diabetes mellitus (%) 1.1
Waist circumference (cm) 88  7
Systolic BP (mm Hg) 139  20
Diastolic BP (mm Hg) 79  10
HDL-cholesterol (mmol/L) 1.3  0.3
Triglycerides (mmol/L) 1.5  1.0
Fasting glucose (mmol/L) 5.3  0.5
Glucose-lowering agents (%) 1.1
Lipid-lowering agents (%) 22.2
Blood pressure-lowering agents (%) 15.4
Changes in metabolic syndrome components
and medication useb
Waist circumference (cm) 3  9
Systolic BP (mm Hg) 9  20
Diastolic BP (mm Hg) 4  12
HDL-cholesterol (mmol/L) 0.3  0.3
Triglycerides (mmol/L) 0.2  0.9
Fasting glucose (mmol/L) 0.1  0.5
Glucose-lowering agents 1.1
Lipid-lowering agents 38.2
Blood pressure-lowering agents 17.6
ACE-inhibitors/AT II antagonists 4.4
Follow-up measurement
HOMA-IRc 1.5 (1.1-2.3)
BP, Blood pressure;HDL, high-density lipoproteins;ACE, angiotensin-conv
insulin resistance.
aContinuous variables are expressed as means with standard deviations.
bContinuous variables are expressed as differences in mean  standard devi
cMedian with interquartile range.PAOD by 51%. This is comparable with results from otherstudies among patients with coronary artery disease where
themetabolic syndrome increased the risk of future vascular
events by 23-63%.9,11,29 In a previous study, we showed
that in patients with a history of vascular disease the meta-
bolic syndrome induced increased vascular risks. The meta-
bolic syndrome was associated with a considerable vascular
risk increment in patients with a history of PAOD or
coronary heart disease, and to a lesser extent in patients
with a history of AAA or cerebrovascular disease.30 In
patients without diabetes or overt cardiovascular disease at
baseline, the risk of cardiovascular events was 2-3 times
higher in the presence of the metabolic syndrome.31 In our
study, the individual metabolic syndrome components
alone were not associated with future vascular events. In
line with this observation, a number of studies found that
most components of the syndrome were not or only mar-
ginally associated with vascular events,9 coronary heart
disease32 or carotid stenosis32 when considered individu-
ally, whereas the metabolic syndrome was associated with
the outcomes examined. Also, the clustering of metabolic
drome components and medication use according to
Metabolic syndrome
✓ ✓
✓ ✓
n  35 n  31 n  64 P value
77.1 74.2 62.5 .34
55  10 61  8 60  10 .08
62.9 67.7 52.4 .63
25.7 19.4 26.6 .01
99  10 96  6 100  12 .01
147  19 138  22 150  19 .01
84  8 76  9 82  9 .01
1.0  0.2 1.3  0.3 0.9  0.2 .01
2.5  2.0 1.9  1.1 2.8  1.4 .01
6.9  2.7 5.9  1.3 6.5  1.4 .01
14.3 16.1 11.1 .01
20.0 38.7 38.1 .06
25.7 25.8 44.4 .01
1  9 10  8 6  5 .01
11  21 8  25 9  22 .94
1  10 4  12 2  10 .45
0.3  0.2 0.2  0.4 0.2  0.2 .08
1.0  1.3 0.2  1.0 0.4  1.5 .01
0.8  2.1 1.1  3.8 0.1  1.2 .01
0 3.3 23.3 .01
54.3 29.0 36.9 .06
17.2 29.0 18.1 .15
14.3 19.3 26.6 .12
1.9 (1.6-3.2) 2.7 (2.0-6.4) 4.1 (3.1-5.8) .01
enzyme;AT II, angiotensin II;HOMA-IR, homeostatic model assessment
categorical variables are expressed as differences in percentages.syn
erting
ation,risk factors had excess influence on carotid intima-media
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Volume 50, Number 1 Vlek et al 67thickness beyond what would have been expected from
merely additive effects.33 The results of the present study
point towards an additional value of identifying the meta-
bolic syndrome beyond recognition of its component traits.
Probably cardiovascular risk increment is also caused by
other factors associated with insulin resistance, like elevated
inflammation, hypoadiponectinemia, and coagulation dis-
orders all seen in metabolic syndrome.34,35
Although the prevalence of abdominal obesity at base-
line was fairly low, in this study, the development from a
non-metabolic syndrome state to a metabolic syndrome
state was associated with a marked increase in waist circum-
ference. This may suggest that an increase in insulin resis-
tance is underlying the development to a metabolic syn-
drome state, supported by the high HOMA-IR values in
patients developing the metabolic syndrome. However,
since baselineHOMA-IR values were not available, conclu-
sions on an increase in insulin resistance cannot be drawn.
Although the obesity criterion at baseline was the least
frequent of the metabolic syndrome criteria, baseline BMI
as well as change in BMI during follow-up significantly
influenced the risk of development of the metabolic syn-
drome or reversion to a non-metabolic syndrome state. In
parallel, a 1.22-fold increased risk of development of the
syndrome was shown for every kg gained over 6 years
among subjects from the DESIR cohort.36 Maintaining
stable weight from young adulthood into middle age has
also been shown to prevent development of the metabolic
syndrome.37
In cardiovascular risk prevention in PAODpatients, the
Fig 3. Changes in the metabolic syndrome componen
follow-up.White bars represent patients withoutmetabol
patients with metabolic syndrome at baseline but not a
syndrome at follow-up but not at baseline; black bars
follow-up. HDL, High-density lipoproteins.importance of weight control should be emphasized, andspecific interventions directed towards modulation of insu-
lin resistance, such as increasing physical activity, may pos-
itively alter vascular prognosis in these patients at very high
risk for cardiovascular events. Emphasis on weight control
and physical activity are most important, as the present
study showed a large effect of BMI decrease on the course
of the metabolic syndrome during follow-up. Apart from
lifestyle changes, treatment with insulin sensitizing agents,
like metformin or thiazolidinediones, can also be consid-
ered in PAOD patients with metabolic syndrome,38 al-
though the benefit of these interventions in this population
should first be investigated in randomized controlled trials.
A reduction in the number of individual metabolic
syndrome components in this study was mainly due to loss
of the HDL-cholesterol or triglycerides criteria. These pa-
tients had lower HOMA-IR levels at follow-up compared
to patients who kept the metabolic syndrome throughout
the study. Possibly these changes in HDL-cholesterol and
plasma triglyceride concentrations may be the result of
increased insulin sensitivity, but information onHOMA-IR
levels at baseline would be necessary to conclude on this
possibility.
Alternatively, the increased use of statins may also
have affected plasma lipids, although statins only mar-
ginally influence HDL-cholesterol (5%) and triglycer-
ides (15%).39,40
Changes in metabolic syndrome components over time
have also been studied in the French DESIR cohort.41
Among 4293 healthy participants aged 30-64 years, the
metabolic syndrome was present in 14% of the population.
ording to metabolic syndrome status at baseline and at
drome at baseline and follow-up; light grey bars represent
w-up; dark grey bars represent patients with metabolic
sent patients with metabolic syndrome at baseline andts acc
ic syn
t follo
repreA quarter of patients with the metabolic syndrome at
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after 3 years of follow-up in that study, compared to 35%
after 5.5 years in our study. This indicates that even in a
high-risk population of patients with PAOD, it is possible
to rid oneself of the metabolic syndrome. In the DESIR
cohort, fasting glucose was the component that normalized
most frequently (40%) after follow-up, whereas in our study
this was the case for HDL-cholesterol and triglycerides,
while the glucose criterion was only lost in 22% of patients.
This difference might be caused by the baseline differences
in glucose abnormalities: 10% in DESIR vs 42% in our
study.
In the present cohort, vascular risk factors were not
optimally treated. For example, less than half of the 221
patients were on statin therapy and the average BP was
high. Many patients did not reach treatment goals for
vascular risk factors. This is in line with studies by others
also showing suboptimal treatment of risk factors in pa-
tients with PAOD and coronary heart disease.42,43 Optimal
treatment leads to a better cardiovascular prognosis in these
high-risk patients. Patients with clinically-evident coronary
heart disease and the metabolic syndrome benefited the
most from aggressive lipid-lowering therapy compared to
patients without the metabolic syndrome, irrespective of
the presence of diabetes.44
We acknowledge limitations in our study. Adequate
measures for insulin resistance (eg, fasting insulin) at base-
line are lacking. It is therefore not possible to draw conclu-
sions as to how insulin resistance is associated with cardio-
vascular prognosis in this study and development of insulin
resistance over time could not be estimated. Also, changes
in physical activity may have influenced the results. As we
utilized measures of BMI instead of waist circumference in
those patients who did not have their waist circumference
measured, it is possible we may have misclassified some
individuals that would have been classified differently based
on waist circumference measures that constitute the ac-
cepted criterion for the metabolic syndrome. Because the
survivors of the cohort were invited and only part of them
agreed to participate in the follow-up examination, possibly
only the less severely affected and younger PAOD patients
participated in the follow-up measurement. This could
have led to an underestimation of the worsening of vascular
risk factors and metabolic syndrome components during
follow-up. As only symptomatic PAOD patients were in-
cluded in this study, we were not able to pronounce upon
the vascular risk in asymptomatic patients with PAOD.
In conclusion, patients with PAOD and the metabolic
syndrome have a 51% higher risk of developing a vascular
event compared to PAOD patients without the metabolic
syndrome. Incident metabolic syndrome is associated with
an increase in abdominal obesity, and a decrease in BMIwas
associated with the disappearance of metabolic syndrome in
PAOD patients. It may be speculated that weight control in
order to reduce incident metabolic syndrome may add to
the prevention of new vascular events in these high-risk
patients.Members of the SMART Study Group are Ale Algra,
MD, PhD; Pieter A. Doevendans, M.D, PhD; Yolanda van
der Graaf, MD, PhD; Diederick E. Grobbee, MD, PhD;
L. Jaap Kappelle, MD, PhD; Willem P.Th.M. Mali, MD,
PhD; Frans L. Moll, MD, PhD; Guy E.H.M. Rutten, MD,
PhD; and Frank L.J. Visseren, MD, PhD.
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